Q4 EPS Estimates for Cytosorbents Lifted by Zacks Small Cap

Cytosorbents Corporation (NASDAQ:CTSO) – Zacks Small Cap boosted their Q4 2025 earnings estimates for shares of Cytosorbents in a report released on Tuesday, January 13th. Zacks Small Cap analyst T. Kerr now expects that the medical research company will earn ($0.04) per share for the quarter, up from their prior estimate of ($0.05). The consensus estimate for Cytosorbents’ current full-year earnings is ($0.30) per share. Zacks Small Cap also issued estimates for Cytosorbents’ FY2026 earnings at ($0.08) EPS.

Cytosorbents (NASDAQ:CTSO) last posted its quarterly earnings results on Thursday, November 13th. The medical research company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.02. Cytosorbents had a negative net margin of 27.77% and a negative return on equity of 101.14%. The business had revenue of $9.49 million during the quarter, compared to the consensus estimate of $10.02 million.

CTSO has been the subject of several other research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Cytosorbents in a research report on Friday, January 9th. HC Wainwright lowered their price target on shares of Cytosorbents from $1.00 to $0.75 and set a “neutral” rating for the company in a report on Friday, November 14th. Finally, D. Boral Capital restated a “buy” rating and issued a $10.00 price objective on shares of Cytosorbents in a research report on Monday, January 12th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $5.38.

Cytosorbents Trading Up 1.6%

NASDAQ CTSO opened at $0.70 on Thursday. The firm has a market cap of $44.09 million, a PE ratio of -3.90 and a beta of 1.32. Cytosorbents has a 1-year low of $0.60 and a 1-year high of $1.61. The stock has a 50-day moving average of $0.70 and a 200-day moving average of $0.86. The company has a current ratio of 2.11, a quick ratio of 1.71 and a debt-to-equity ratio of 1.61.

Institutional Trading of Cytosorbents

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Goldman Sachs Group Inc. grew its stake in shares of Cytosorbents by 149.2% in the first quarter. Goldman Sachs Group Inc. now owns 62,662 shares of the medical research company’s stock worth $63,000 after acquiring an additional 37,519 shares during the last quarter. Avenir Corp boosted its stake in Cytosorbents by 0.3% during the 2nd quarter. Avenir Corp now owns 5,058,537 shares of the medical research company’s stock valued at $6,475,000 after purchasing an additional 13,619 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Cytosorbents by 3.7% in the 3rd quarter. Vanguard Group Inc. now owns 2,204,294 shares of the medical research company’s stock worth $2,059,000 after purchasing an additional 79,535 shares in the last quarter. GSA Capital Partners LLP purchased a new position in shares of Cytosorbents in the third quarter worth $105,000. Finally, CM Management LLC lifted its holdings in shares of Cytosorbents by 3.1% during the third quarter. CM Management LLC now owns 1,288,128 shares of the medical research company’s stock valued at $1,203,000 after purchasing an additional 38,128 shares in the last quarter. 32.87% of the stock is owned by hedge funds and other institutional investors.

About Cytosorbents

Cytosorbents Corporation, founded in 2011 and headquartered in Princeton, New Jersey, is a medical device company focused on critical care and extracorporeal blood purification. The company’s flagship product, CytoSorb, is a hemoadsorption cartridge designed to remove excessive inflammatory mediators such as cytokines, bilirubin and myoglobin from a patient’s blood. By targeting the molecular drivers of hyperinflammation, CytoSorb is intended to stabilize patients undergoing septic shock, cardiac surgery, trauma and organ failure.

CytoSorb has secured regulatory clearance in Europe (CE mark) and is available in more than 65 countries, with a growing presence in Asia, the Middle East and Latin America.